These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 3044554)

  • 21. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy.
    Goldstein EJ; Snydman DR
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii29-36. PubMed ID: 15150181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties.
    Hammond ML
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii7-9. PubMed ID: 15150178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimicrobial susceptibility patterns of anaerobic bacteria in relation to therapy.
    García-Rodríguez J; García-Sánchez J
    Chemioterapia; 1987 Jun; 6(2 Suppl):49-52. PubMed ID: 3509479
    [No Abstract]   [Full Text] [Related]  

  • 24. Meropenem, a new carbapenem antibiotic.
    Fish DN; Singletary TJ
    Pharmacotherapy; 1997; 17(4):644-69. PubMed ID: 9250544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The aerobic bacteria spectrum of pyogenic infections in the maxillofacial region and its change as affected by antimicrobial chemotherapy].
    Schulz S; Haerting J
    Z Gesamte Hyg; 1984 May; 30(5):273-5. PubMed ID: 6475147
    [No Abstract]   [Full Text] [Related]  

  • 26. Antibacterial properties of benzoyl peroxide in aerobic and anaerobic conditions.
    Burkhart CG; Burkhart CN
    Int J Dermatol; 2006 Nov; 45(11):1373-4. PubMed ID: 17076732
    [No Abstract]   [Full Text] [Related]  

  • 27. In vitro activity of meropenem compared with imipenem, metronidazole, ampicillin, and ampicillin/sulbactam against anaerobes.
    Schumacher U; Manncke B; Gerbracht K; Werner H
    Arzneimittelforschung; 1994 Jul; 44(7):859-62. PubMed ID: 7945523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Sensitivity tests to antibiotics for aerobes and anaerobes in clinical practice].
    Brenciaglia MI; Rivanera D; Lilli D; Filadoro F
    Nuovi Ann Ig Microbiol; 1982; 33(2-3):349-74. PubMed ID: 7187036
    [No Abstract]   [Full Text] [Related]  

  • 29. Fatal Acinetobacter baumannii infection with discordant carbapenem susceptibility.
    Lesho E; Wortmann G; Moran K; Craft D
    Clin Infect Dis; 2005 Sep; 41(5):758-9. PubMed ID: 16080102
    [No Abstract]   [Full Text] [Related]  

  • 30. Parenteral carbapenems.
    Shah PM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():175-80. PubMed ID: 18154543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Characteristics of ertapenem use in critical state patients].
    Beloborodov VB
    Antibiot Khimioter; 2011; 56(3-4):10-2, 14-6. PubMed ID: 21913404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. L-627, a novel carbapenem: in-vitro activity against anaerobes.
    García-Rodríguez JA; García-Sánchez JE; Trujillano-Martín I; García-Sánchez E; García-García I; Fresnadillo-Martínez J
    J Antimicrob Chemother; 1994 Jan; 33(1):183-6. PubMed ID: 8157563
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical investigation on target value of T>MIC in carbapenems].
    Mikamo H; Yamagishi Y; Tanaka K; Watanabe K
    Jpn J Antibiot; 2008 Apr; 61(2):73-81. PubMed ID: 18669417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ceftizoxime: a third-generation cephalosporin active against anaerobic bacteria. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.
    CMAJ; 1990 Jun; 142(11):1209-12. PubMed ID: 2188719
    [No Abstract]   [Full Text] [Related]  

  • 35. A 7-year survey of drug resistance in aerobic and anaerobic fecal bacteria of surgical inpatients: clinical relevance and relation to local antibiotic consumption.
    Kling PA; Ostensson R; Granström S; Burman LG
    Scand J Infect Dis; 1989; 21(6):589-96. PubMed ID: 2617202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic implications of bacteriologic findings in mixed aerobic-anaerobic infections.
    Finegold SM; Wexler HM
    Antimicrob Agents Chemother; 1988 May; 32(5):611-6. PubMed ID: 3293522
    [No Abstract]   [Full Text] [Related]  

  • 37. In-vitro susceptibility testing of anaerobes with 10-micrograms imipenem discs.
    Meijer-Severs GJ; van Santen E
    J Antimicrob Chemother; 1987 Sep; 20(3):456. PubMed ID: 3479418
    [No Abstract]   [Full Text] [Related]  

  • 38. Susceptibility of Mycobacterium fallax to imipenem and twenty other antimicrobial agents.
    Haas H; Zubi R; Sacks TG
    Eur J Clin Microbiol; 1984 Oct; 3(5):489-91. PubMed ID: 6594239
    [No Abstract]   [Full Text] [Related]  

  • 39. Bactericidal activity of imipenem in serum.
    Machka K
    Eur J Clin Microbiol; 1984 Oct; 3(5):495-7. PubMed ID: 6594240
    [No Abstract]   [Full Text] [Related]  

  • 40. Ceftriaxone prophylaxis in surgery.
    Villiger JW; Taylor KM
    N Z Med J; 1990 May; 103(890):251. PubMed ID: 2188174
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.